drugset / Trial / NCT00667537

PK in Pts With HRPC & Skeletal Metastes

NCT00667537

Phase 1 Completed 6 enrolled Bayer
NaSingle-groupOpen-labelBasic science

Summary

Primary objective: To investigate the biodistribution, radiation dosimetry, and pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body weight \[b.w.\] \[=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization\], 6 weeks apart). Secondary objectives: To determine the safety of IV injections of Xofigo after two separate injections (6 weeks apart), to evaluate treatment response (antitumour effect in osteoblastic bone metastases) of Xofigo treatment consisting of two injections of activity 100 kBq/kg b.w. (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization), 6 weeks apart and to evaluate long term radiation toxicity and to collect survival data at 6 and 12 months after the first injection

Timeline

Start
2007-07
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Radium-223 dichloride Other / unclassified 0.1 mbq/kg Intravenous

Indications